These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 37852306

  • 1. Efficacy and safety of apremilast in patients with moderate-to-severe genital psoriasis: Results from DISCREET, a phase 3 randomized, double-blind, placebo-controlled trial.
    Merola JF, Parish LC, Guenther L, Lynde C, Lacour JP, Staubach P, Cheng S, Paris M, Picard H, Deignan C, Jardon S, Chen M, Papp KA.
    J Am Acad Dermatol; 2024 Mar; 90(3):485-493. PubMed ID: 37852306
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial.
    Stein Gold L, Papp K, Pariser D, Green L, Bhatia N, Sofen H, Albrecht L, Gooderham M, Chen M, Paris M, Wang Y, Callis Duffin K.
    J Am Acad Dermatol; 2022 Jan; 86(1):77-85. PubMed ID: 34343599
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and Safety of Apremilast in Systemic- and Biologic-Naive Patients With Moderate Plaque Psoriasis: 52-Week Results of UNVEIL.
    Stein Gold L, Bagel J, Lebwohl M, Jackson JM, Chen R, Goncalves J, Levi E, Duffin KC.
    J Drugs Dermatol; 2018 Feb 01; 17(2):221-228. PubMed ID: 29462231
    [Abstract] [Full Text] [Related]

  • 4. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE).
    Reich K, Gooderham M, Green L, Bewley A, Zhang Z, Khanskaya I, Day RM, Goncalves J, Shah K, Piguet V, Soung J.
    J Eur Acad Dermatol Venereol; 2017 Mar 01; 31(3):507-517. PubMed ID: 27768242
    [Abstract] [Full Text] [Related]

  • 5. Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial.
    Ohtsuki M, Okubo Y, Komine M, Imafuku S, Day RM, Chen P, Petric R, Maroli A, Nemoto O.
    J Dermatol; 2017 Aug 01; 44(8):873-884. PubMed ID: 28391657
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2).
    Paul C, Cather J, Gooderham M, Poulin Y, Mrowietz U, Ferrandiz C, Crowley J, Hu C, Stevens RM, Shah K, Day RM, Girolomoni G, Gottlieb AB.
    Br J Dermatol; 2015 Dec 01; 173(6):1387-99. PubMed ID: 26357944
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study.
    Van Voorhees AS, Stein Gold L, Lebwohl M, Strober B, Lynde C, Tyring S, Cauthen A, Sofen H, Zhang Z, Paris M, Wang Y.
    J Am Acad Dermatol; 2020 Jul 01; 83(1):96-103. PubMed ID: 32032692
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of apremilast in pediatric patients with moderate-to-severe plaque psoriasis: 16-week results from SPROUT, a randomized controlled trial.
    Fiorillo L, Becker E, de Lucas R, Belloni-Fortina A, Armesto S, Elewski B, Maes P, Oberoi RK, Paris M, Zhang W, Zhang Z, Arkin L.
    J Am Acad Dermatol; 2024 Jun 01; 90(6):1232-1239. PubMed ID: 38266683
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study.
    Reich K, Gooderham M, Bewley A, Green L, Soung J, Petric R, Marcsisin J, Cirulli J, Chen R, Piguet V.
    J Eur Acad Dermatol Venereol; 2018 Mar 01; 32(3):397-402. PubMed ID: 29220542
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study.
    Papp KA, Kaufmann R, Thaçi D, Hu C, Sutherland D, Rohane P.
    J Eur Acad Dermatol Venereol; 2013 Mar 01; 27(3):e376-83. PubMed ID: 23030767
    [Abstract] [Full Text] [Related]

  • 15. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1).
    Papp K, Reich K, Leonardi CL, Kircik L, Chimenti S, Langley RG, Hu C, Stevens RM, Day RM, Gordon KB, Korman NJ, Griffiths CE.
    J Am Acad Dermatol; 2015 Jul 01; 73(1):37-49. PubMed ID: 26089047
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis With Lower BSA: Week 16 Results from the UNVEIL Study.
    Strober B, Bagel J, Lebwohl M, Stein Gold L, Jackson JM, Chen R, Goncalves J, Levi E, Callis Duffin K.
    J Drugs Dermatol; 2017 Aug 01; 16(8):801-808. PubMed ID: 28809995
    [Abstract] [Full Text] [Related]

  • 17. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3).
    Edwards CJ, Blanco FJ, Crowley J, Birbara CA, Jaworski J, Aelion J, Stevens RM, Vessey A, Zhan X, Bird P.
    Ann Rheum Dis; 2016 Jun 01; 75(6):1065-73. PubMed ID: 26792812
    [Abstract] [Full Text] [Related]

  • 18. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial.
    Armstrong AW, Gooderham M, Warren RB, Papp KA, Strober B, Thaçi D, Morita A, Szepietowski JC, Imafuku S, Colston E, Throup J, Kundu S, Schoenfeld S, Linaberry M, Banerjee S, Blauvelt A.
    J Am Acad Dermatol; 2023 Jan 01; 88(1):29-39. PubMed ID: 35820547
    [Abstract] [Full Text] [Related]

  • 19. Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis.
    Bissonnette R, Pariser DM, Wasel NR, Goncalves J, Day RM, Chen R, Sebastian M.
    J Am Acad Dermatol; 2016 Jul 01; 75(1):99-105. PubMed ID: 27021239
    [Abstract] [Full Text] [Related]

  • 20. Apremilast for the treatment of moderate-to-severe palmoplantar psoriasis: results from a double-blind, placebo-controlled, randomized study.
    Bissonnette R, Haydey R, Rosoph LA, Lynde CW, Bukhalo M, Fowler JF, Delorme I, Gagné-Henley A, Gooderham M, Poulin Y, Barber K, Jenkin P, Landells I, Pariser DM.
    J Eur Acad Dermatol Venereol; 2018 Mar 01; 32(3):403-410. PubMed ID: 29055155
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.